Home/Nymox Pharmaceutical/Chris Riley

CR

Chris Riley

Former Director

Nymox Pharmaceutical

Therapeutic Areas

Nymox Pharmaceutical Pipeline

Drug	Indication	Phase
Fexapotide Triflutate (NX-1207)	Benign Prostatic Hyperplasia (BPH)	Phase 3

Leadership Team at Nymox Pharmaceutical

Dr. Paul Averback, MD, FRCP(C)

Founder, Chief Executive Officer, and Chairman of the Board

Former Chief Financial Officer

Robert J. Molinari

Former Chief Operating Officer

View full Nymox Pharmaceutical profile